From GlobeNewswire:

Cabaletta Bio, Inc. (Nasdaq: CABA) announced CEO Steven Nichtberger, M.D. will present at the J.P. Morgan Healthcare Conference on January 9, 2024 in San Francisco, CA. A live webcast available on the company’s website with replays for 30 days. The company focuses on developing targeted cell therapies for autoimmune diseases with its CARTA and CAART strategies.

The CABA™ platform includes CABA-201, a 4-1BB-containing fully human CD19-CAR T being evaluated in various autoimmune diseases. The company also has multiple clinical-stage candidates under its CAART strategy. Cabaletta Bio is working on potentially curative therapies that offer deep and durable responses for patients with different autoimmune diseases. The company’s headquarters and labs are located in Philadelphia, PA.



Read more: Cabaletta Bio to Present at the 42nd Annual J.P. Morgan